These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 32936732)

  • 1. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
    Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
    Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
    Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
    Soni B; Kabra R; Singh S
    J Interferon Cytokine Res; 2021 Jul; 41(7):244-257. PubMed ID: 34280026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
    Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
    Front Immunol; 2021; 12():809244. PubMed ID: 35046961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccinations: The unknowns, challenges, and hopes.
    Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus vaccine development: from SARS and MERS to COVID-19.
    Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will Omicron end the pandemic? Here's what experts say.
    Adam D
    Nature; 2022 Feb; 602(7895):20-21. PubMed ID: 35102287
    [No Abstract]   [Full Text] [Related]  

  • 15. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches.
    Marei HE; Althani A; Afifi N; Pozzoli G; Caceci T; Angelini F; Cenciarelli C
    Mol Biol Rep; 2021 Sep; 48(9):6513-6524. PubMed ID: 34398427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in virus-like particle-based SARS-CoV-2 vaccines.
    Hao X; Yuan F; Yao X
    Front Cell Infect Microbiol; 2024; 14():1406091. PubMed ID: 38988812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
    Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP
    J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
    Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
    Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.